A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans.
Level 1 - systematic review of randomized trials
Systematic review of 13 within-subject, double-blind, placebo-controlled laboratory trials
PubMed 31616329 · doi:10.3389/fpsyt.2019.00704
What was done
A systematic review was conducted in September 2018 to evaluate human laboratory evidence of tramadol abuse potential. The search identified 13 within-subject, double-blind, placebo-controlled human laboratory studies comparing tramadol to other opioid comparators. Findings were synthesized by administration route (oral vs. parenteral) and population (individuals with vs. without current physical opioid dependence), measuring self-reported positive and negative drug effects, observer ratings, pharmacodynamic time course, opioid drug identification, and drug self-administration.
What was found
The abstract reports no numerical values, effect sizes, or statistical metrics. Qualitatively, across the 13 trials, tramadol displayed lower relative abuse potential than comparator opioids. Peak positive subjective ratings occurred with oral dosing in non-opioid-dependent individuals. Compared to comparator opioids, tramadol elicited substantial negative subjective effect ratings, had a slower onset of action, and was less frequently identified by subjects as an opioid. Abuse potential appeared to decrease with increasing doses, parenteral administration, or in the presence of physical opioid dependence. However, in the single study measuring self-administration, tramadol produced higher self-administration rates than comparator opioids.
Why it matters
This synthesis suggests that tramadol possesses a distinct and generally lower experimental abuse liability profile compared to conventional opioids, which may reduce risk for dose escalation or transition to parenteral routes.
Limits
The abstract reports no numerical data, confidence intervals, or total participant sample sizes across the 13 trials. Only a single study assessed actual drug self-administration behavior. Human laboratory abuse-liability paradigms may not fully mirror complex real-world polysubstance use or epidemiological diversion patterns.